Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020097421 - COMBINATION TREATMENT FOR RESISTANT HYPERTENSION

Publication Number WO/2020/097421
Publication Date 14.05.2020
International Application No. PCT/US2019/060401
International Filing Date 08.11.2019
IPC
C07K 14/58 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
58Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide (ANP); Cardionatrin; Cardiodilatin
A61P 13/12 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
A61P 9/12 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
12Antihypertensives
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
Applicants
  • MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH [US]/[US]
  • BURNETT, Jr, John C. [US]/[US]
  • DZHOYASHVILI, Nina [US]/[US]
Inventors
  • BURNETT, Jr, John C.
  • DZHOYASHVILI, Nina
Agents
  • KAYTOR, Elizabeth N.
  • FINN III, J. Patrick
Priority Data
62/758,00909.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMBINATION TREATMENT FOR RESISTANT HYPERTENSION
(FR) TRAITEMENT COMBINÉ POUR L'HYPERTENSION RÉSISTANTE
Abstract
(EN)
Materials and methods for treating hypertension (including resistant hypertension) with a combination of an M-atrial natriuretic peptide (MANP) and a diuretic agent (e.g., furosemide) are described herein.
(FR)
L'invention concerne des substances et des procédés pour traiter l'hypertension (y compris l'hypertension résistante) avec une combinaison d'un peptide natriurétique M-atrial (MANP) et d'un agent diurétique (par exemple, furosémide).
Latest bibliographic data on file with the International Bureau